CNCR - Karyopharm: Another 2 Year Wait For Data May, 05 2022 12:21 PM Loncar Cancer Immunotherapy ETF KPTI has been devastated by the SIENDO trial failure. The next trial's data will be read out 2 years later. Until then, I see little upside for the stock. For further details see: Karyopharm: Another 2 Year Wait For Data